Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URT035
MIFTS: 38

Urethral Benign Neoplasm

Categories: Cancer diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Urethral Benign Neoplasm

About this section

MalaCards integrated aliases for Urethral Benign Neoplasm:

Name: Urethral Benign Neoplasm 11 14
Urethral Neoplasms 43 71
Malignant Neoplasm of Urethra 71
Neoplasm of Urethra 11
Urethral Carcinoma 71
Neoplasm. Urethra 11
Urethral Neoplasm 16

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:730
MeSH 43 D014523
NCIt 49 C3428
SNOMED-CT 68 126883004
UMLS 71 C0041971 C0153620 C0700101
Sources

Summaries for Urethral Benign Neoplasm

About this section

MalaCards based summary: Urethral Benign Neoplasm, also known as urethral neoplasms, is related to urethra leiomyoma and urethra cancer. An important gene associated with Urethral Benign Neoplasm is KRT20 (Keratin 20), and among its related pathways/superpathways are Cytoskeletal Signaling and Cellular roles of Anthrax toxin. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and endothelial, and related phenotypes are renal/urinary system and cellular
Sources

Related Diseases for Urethral Benign Neoplasm

About this section

Diseases related to Urethral Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 574)
# Related Disease Score Top Affiliating Genes
1 urethra leiomyoma 32.3 MME CALD1
2 urethra cancer 30.4 PAX8 KRT7 KLK3
3 bile duct signet ring cell carcinoma 10.4 KRT7 KRT20
4 mucinous bronchioloalveolar adenocarcinoma 10.4 KRT7 KRT20
5 endometrial transitional cell carcinoma 10.4 KRT7 KRT20
6 leukoplakia of penis 10.4 KRT7 CEACAM5
7 lacrimal gland mucoepidermoid carcinoma 10.4 KRT7 KRT20
8 anal canal adenocarcinoma 10.4 KRT7 KRT20
9 thymus adenocarcinoma 10.4 KRT20 CEACAM5
10 eccrine papillary adenoma 10.4 KRT20 CEACAM5
11 aggressive digital papillary adenocarcinoma 10.4 KRT7 CEACAM5
12 adenosquamous bile duct carcinoma 10.4 KRT7 CEACAM5
13 apocrine adenoma 10.4 KRT7 CEACAM5
14 epithelial predominant wilms' tumor 10.4 KRT7 AMACR
15 vulval paget's disease 10.4 KRT7 CEACAM5
16 urinary bladder small cell neuroendocrine carcinoma 10.4 KRT7 KRT20
17 seminal vesicle cystadenoma 10.3 KLK3 CEACAM5
18 adenoid basal cell carcinoma 10.3 KRT7 CEACAM5
19 bladder urachal carcinoma 10.3 KRT7 AMACR
20 biliary papillomatosis 10.3 KRT7 CEACAM5
21 jejunal cancer 10.3 KRT7 CEACAM5
22 nephrogenic adenofibroma 10.3 KRT7 AMACR
23 eyelid carcinoma 10.3 KRT7 KRT20
24 urachus cancer 10.3 KRT7 AMACR
25 mucinous intrahepatic cholangiocarcinoma 10.3 KRT7 CEACAM5
26 laryngeal mucoepidermoid carcinoma 10.3 KLK3 CEACAM5
27 meibomian cyst 10.3 KRT7 KRT20
28 appendiceal neoplasm 10.3 KRT7 CEACAM5
29 transverse colon cancer 10.3 KRT20 CEACAM5
30 ascending colon cancer 10.3 KRT7 CEACAM5
31 bladder lymphoma 10.3 MME KRT20
32 vaginal adenoma 10.3 KRT7 KRT20
33 cholangiolocellular carcinoma 10.3 KRT7 CEACAM5
34 vaginal endometrial stromal tumor 10.3 MME CALD1
35 mixed endometrial stromal and smooth muscle tumor 10.3 MME CALD1
36 fallopian tube leiomyoma 10.3 MME CALD1
37 fallopian tube benign neoplasm 10.3 MME CALD1
38 lung sarcoma 10.3 CALD1 CALB2
39 liver lymphoma 10.3 MME CEACAM5
40 hidrocystoma 10.3 KRT7 CEACAM5
41 prostate embryonal rhabdomyosarcoma 10.3 KLK3 CALD1
42 xanthogranulomatous pyelonephritis 10.3 MME KRT7
43 mucinous cystadenofibroma 10.3 PAX8 KRT7
44 papillary thymic adenocarcinoma 10.3 CEACAM5 CALB2
45 secretory meningioma 10.3 KRT7 CEACAM5
46 atypical polypoid adenomyoma 10.3 MME CALD1
47 pancreatic serous cystadenocarcinoma 10.3 KRT7 KRT20 CEACAM5
48 hepatoid adenocarcinoma 10.3 KRT7 CEACAM5
49 vaginal tubulovillous adenoma 10.3 KRT7 KRT20 CEACAM5
50 urinary bladder villous adenoma 10.3 KRT7 KRT20 CEACAM5

Comorbidity relations with Urethral Benign Neoplasm via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Cancer
Hydronephrosis Prostate Cancer
Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Urethral Benign Neoplasm:



Diseases related to Urethral Benign Neoplasm
Sources

Symptoms & Phenotypes for Urethral Benign Neoplasm

About this section

MGI Mouse Phenotypes related to Urethral Benign Neoplasm:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.56 CALD1 ESR1 FUT4 KRT7 PAX2 PAX8
2 cellular MP:0005384 9.32 CEACAM5 ESR1 FUT4 KRT7 MME PAX2
Sources

Drugs & Therapeutics for Urethral Benign Neoplasm

About this section

Drugs for Urethral Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
4
Vinblastine Approved Phase 3 865-21-4 241903 13342
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
6
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
7
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
8
Avelumab Approved, Investigational Phase 3 1537032-82-8
9 Albumin-Bound Paclitaxel Phase 3
10 Antimitotic Agents Phase 3
11 Tubulin Modulators Phase 3
12 Angiogenesis Inhibitors Phase 3
13 Liposomal doxorubicin Phase 3
14 Folic Acid Antagonists Phase 3
15 Dermatologic Agents Phase 3
16 Antirheumatic Agents Phase 3
17 Endothelial Growth Factors Phase 3
18 Mitogens Phase 3
19 Immunoglobulins Phase 3
20 Antibodies Phase 3
21 Antineoplastic Agents, Immunological Phase 3
22 Immunologic Factors Phase 3
23 Halichondrin B Phase 3 5915307
24 Antibodies, Monoclonal Phase 3
25
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
26
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
27
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
28
Aflibercept Approved Phase 2 862111-32-8 124490314
29
Ifosfamide Approved Phase 2 3778-73-2 3690
30
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
31
Mitomycin Approved Phase 2 50-07-7 5746
32
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
33
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
34
Lonafarnib Approved, Investigational Phase 2 193275-84-2 148195
35
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
36
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
37
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
38
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
39
Ramucirumab Approved, Investigational Phase 2 947687-13-0
40
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
41
Afatinib Approved Phase 2 439081-18-2, 850140-72-6 53445376 10184653
42
Propranolol Approved, Investigational Phase 2 318-98-9, 525-66-6 62882 4946
43
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
44
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
45
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
46
Fluorouracil Approved Phase 2 51-21-8 3385
47
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
48
Nivolumab Approved Phase 2 946414-94-4
49
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
50
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study - Unknown status NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
2 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
3 Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
4 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
5 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma Completed NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
6 A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
7 A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy Recruiting NCT04579224 Phase 3 Docetaxel;Eribulin Mesylate;Gemcitabine Hydrochloride;Paclitaxel
8 MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer Recruiting NCT05092958 Phase 3 Avelumab;Cabozantinib S-malate
9 A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy Unknown status NCT01118039 Phase 2 sunitinib malate
10 A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
11 A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma Completed NCT01688999 Phase 2 Cabozantinib
12 A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced, Unresectable Transitional Cell Carcinoma of the Urothelium Completed NCT00077688 Phase 2 TOCOSOL Paclitaxel
13 A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy Completed NCT00749892 Phase 2 Erlotinib Hydrochloride
14 A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2 pazopanib hydrochloride
15 A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function. Completed NCT02665039 Phase 2 Vinflunine;Gemcitabine;Carboplatin
16 A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
17 Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate
18 A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer Completed NCT00661609 Phase 2 AZD4877
19 A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium Completed NCT00407485 Phase 2
20 Phase II Trial of Neoadjuvant, Multi-Agent Chemotherapy For Locally Advanced Urothelial Cancer Completed NCT00080795 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;ifosfamide
21 Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Completed NCT00072150 Phase 2 bortezomib
22 Phase II Trial Of Pemetrexed Disodium And Gemcitabine In Advanced Urothelial Cancer Completed NCT00053209 Phase 2 gemcitabine hydrochloride;pemetrexed disodium
23 A Sequential Approach to the Treatment of Muscle Invasive, Non-Metastatic Urothelial Carcinoma of the Bladder: A Phase II Trial of Neoadjuvant Gemcitabine, Paclitaxel and Carboplatin With Molecular Correlates Completed NCT00045630 Phase 2 carboplatin;gemcitabine;paclitaxel
24 Multicenter Study of the Quality of Life of Patients With Invasive Urothelial Cancer Treated With Conservative Surgery Followed by Cisplatin, Fluorouracil and Radiotherapy Completed NCT00006111 Phase 2 cisplatin;fluorouracil
25 Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Advanced Urothelial Carcinoma With Renal Insufficiency Completed NCT00005644 Phase 2 gemcitabine hydrochloride;paclitaxel
26 PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM Completed NCT00002914 Phase 2 piritrexim
27 Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
28 Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) With Avelumab in Muscle Invasive Bladder Cancer Completed NCT03617913 Phase 2 Avelumab;Cisplatin;Fluorouracil;Mitomycin
29 A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium Completed NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
30 Phase 2 Study With the Multi-Targeted Tyrosine-Kinase Inhibitor Pazopanib (GW786034) for Patients With Relapsed or Refractory Urothelial Cancer Completed NCT01031875 Phase 2 pazopanib hydrochloride
31 Evaluation of ZD1839 (NSC #715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II Completed NCT00014144 Phase 2 gefitinib
32 A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract Completed NCT00003175 Phase 2 fluorouracil
33 Phase II Study of Irinotecan in Patients With Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT00066612 Phase 2 irinotecan hydrochloride
34 Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997 Completed NCT00006351 Phase 2 gemcitabine hydrochloride;lonafarnib
35 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors Completed NCT00006026 Phase 2 rubitecan
36 A Phase I/II Single-Arm Trial to Evaluate the Combination of Cisplatin and Gemcitabine With the mTOR Inhibitor Temsirolimus for First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
37 Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium Completed NCT00004223 Phase 2 docetaxel;gemcitabine hydrochloride
38 Phase II Evaluation of Carboplatin, Paclitaxel and Gemcitabine Followed by Concurrent Cisplatin and Radiation Therapy in Patients With Locally Advanced or Recurrent Urothelial Malignancy Completed NCT00055835 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
39 A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium Completed NCT00021099 Phase 2 ixabepilone
40 A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER Completed NCT00009867 Phase 2 arsenic trioxide
41 Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder Completed NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
42 A Randomized Phase II Trial of Carboplatin and Gemcitabine +/- Vandetanib in First Line Treatment of Advanced Urothelial Cell Cancer in Patients Who Are Not Suitable to Receive Cisplatin Completed NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
43 An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy Completed NCT01282463 Phase 2 Docetaxel
44 A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer Recruiting NCT03288545 Phase 1, Phase 2 enfortumab vedotin (EV);pembrolizumab;cisplatin;carboplatin;gemcitabine
45 Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer Recruiting NCT02122172 Phase 2 afatinib dimaleate
46 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib S-malate
47 A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
48 A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Recruiting NCT04940299 Phase 2
49 Propranolol Hydrochloride and Pembrolizumab in Patients With Recurrent or Metastatic Urothelial Carcinoma: A Single Center Phase II Trial Recruiting NCT04848519 Phase 2 Pembrolizumab;Propranolol Hydrochloride
50 A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy Active, not recruiting NCT03219333 Phase 2 Enfortumab vedotin

Search NIH Clinical Center for Urethral Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


pembrolizumab

Cochrane evidence based reviews: urethral neoplasms

Sources

Genetic Tests for Urethral Benign Neoplasm

About this section
Sources

Anatomical Context for Urethral Benign Neoplasm

About this section

Organs/tissues related to Urethral Benign Neoplasm:

MalaCards : Prostate, Kidney, Endothelial, Lung
Sources

Publications for Urethral Benign Neoplasm

About this section

Articles related to Urethral Benign Neoplasm:

(show all 15)
# Title Authors PMID Year
1
Urethral caruncle in penile urethra in a young male. 62
35136298 2022
2
Multimodality imaging of the male urethra: trauma, infection, neoplasm, and common surgical repairs. 62
31440803 2019
3
Clear Cell Adenocarcinoma of Female Urethra. 62
28892907 2017
4
Metastatic Prostate Cancer to the Urethra Masquerading as Urothelial Carcinoma. 62
27335787 2016
5
Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. 62
24389164 2014
6
Primary urethral transitional cell carcinoma presenting as a urethral caruncle. 62
17333433 2007
7
A case of urethral recurrence found 15 years after radical cystectomy. 62
10585124 1999
8
[Orthotopic ileal neobladders in men and women: techniques and comparison]. 62
9026229 1996
9
Primary non-Hodgkin's lymphoma of the male urethra. A case report and review of the literature. 62
8540167 1995
10
Bladder sparing surgery for locally advanced female urethral cancer. 62
8371372 1993
11
[Transitional cell carcinoma of the urethra in patients after cystectomy for bladder carcinoma]. 62
1492273 1992
12
Case profile: prostatic adenoma masquerading as primary urethral neoplasm. 62
2459832 1988
13
Carcinoma of the female urethra: combined iridium Ir 192 interstitial and external beam radiotherapy. 62
3114892 1987
14
Urethral meatal carcinoma following cystourethrectomy for bladder carcinoma. 62
1246115 1976
15
[Urethral neoplasm]. 62
14011493 1962
Sources

Variations for Urethral Benign Neoplasm

About this section
Sources

Expression for Urethral Benign Neoplasm

About this section
Search GEO for disease gene expression data for Urethral Benign Neoplasm.
Sources

Pathways for Urethral Benign Neoplasm

About this section

Pathways related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytoskeletal Signaling 3
11.41 KRT7 KRT5 KRT20 CALD1
2
Cellular roles of Anthrax toxin 61
10.43 PGR ESR1
3
Mammary gland development pathway - Puberty (Stage 2 of 4) 74
10.07 PGR ESR1
Sources

GO Terms for Urethral Benign Neoplasm

About this section

Biological processes related to Urethral Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 intermediate filament organization GO:0045109 10.03 KRT7 KRT5 KRT20
2 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.84 PAX8 PAX2
3 pronephros development GO:0048793 9.83 PAX8 PAX2
4 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.81 PAX8 PAX2
5 metanephric epithelium development GO:0072207 9.8 PAX8 PAX2
6 positive regulation of RNA polymerase II transcription preinitiation complex assembly GO:0045899 9.78 TP53 ESR1
7 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.76 PAX2 PAX8
8 metanephric distal convoluted tubule development GO:0072221 9.73 PAX2 PAX8
9 negative regulation of miRNA maturation GO:1903799 9.72 TP53 ESR1
10 metanephric nephron tubule formation GO:0072289 9.71 PAX2 PAX8
11 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.67 PAX8 PAX2
12 positive regulation of metanephric DCT cell differentiation GO:2000594 9.62 PAX8 PAX2
13 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.56 PAX8 PAX2
14 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.46 PAX8 PAX2
15 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.26 PAX8 PAX2
16 pronephric field specification GO:0039003 8.92 PAX8 PAX2
Sources

Sources for Urethral Benign Neoplasm

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....